Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew Plc LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -35.50 -2.08% 1,667.50 1,667.00 1,668.00 1,704.50 1,640.50 1,689.50 811,456 14:07:32
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3,874.2 560.2 51.7 30.0 14,586

Smith & Nephew Share Discussion Threads

Showing 826 to 850 of 900 messages
Chat Pages: 36  35  34  33  32  31  30  29  28  27  26  25  Older
DateSubjectAuthorDiscuss
12/2/2019
16:31
Had a read of the conference call transcript, where the CEO makes it crystal clear they are assessing potential acquisitions. Does not necessarily mean the FT story is accurate, however would not rule it out.
essentialinvestor
12/2/2019
03:41
Nuvasive shareholder list is such that I reckon S&N would be happy to use paper.They don't have to pander to private clients,approaching 90% is institutionally held.Top 10 Institutional Holdings by Shares HeldName Reporting Date Total Holdings Sorted in descending order. Position Value OutstandingShares OwnedBlackrock Inc. 12/31/18 6.2M $308.7M 12.12%Vanguard Group, Inc. (The) 09/30/18 4.7M $230.9M 9.06%Champlain Investment Partners, LLC 09/30/18 3.2M $156.4M 6.14%Price (T.Rowe) Associates Inc 09/30/18 2.3M $116.1M 4.56%State Street Corporation 09/30/18 2.0M $98.3M 3.86%Goldman Sachs Group, Inc. 09/30/18 1.5M $76.0M 2.98%Bank of America Corporation 09/30/18 1.4M $69.8M 2.74%Eagle Asset Management Inc 09/30/18 1.4M $69.2M 2.71%Dimensional Fund Advisors LP 09/30/18 1.3M $63.2M 2.48%Fisher Asset Management, LLC 12/31/18 1.3M $63.1M 2.47%
steeplejack
11/2/2019
12:34
Jack, how would that be funded. It could not be all debt surely?. With the 500 USD net debt, it would leave SN. With 4 billion of net debt, very approx.
essentialinvestor
11/2/2019
12:30
Nuvasive NUVA are a buy with Charles Schwab which is encouraging.
steeplejack
11/2/2019
12:20
Second small lot at just over 14.32.
essentialinvestor
11/2/2019
12:20
Smith & Nephew was the biggest faller on the FTSE 100 this morning with shares down more than four per cent on reports it is in talks to buy US spine technology Nuvasive in a $3bn (£2.32bn) deal. Shares fell 4.39 per cent to 1,448p today, having closed on Friday at 1,515p. The Financial Times reported the potential deal on Friday after markets closed, sending Nuvasive’s share price up 25 per cent in after hours trading.
steeplejack
11/2/2019
11:59
NuVasive has $500 in debt, it's market cap is near $3 Billion
essentialinvestor
11/2/2019
09:14
Bought a few back at 14.52. If the acquisition reports this morning are accurate, SN. may be available lower down, as the price mentioned looks on the steep side. Just imv only.
essentialinvestor
11/2/2019
08:18
Appreciate the views guys, thanks.
essentialinvestor
08/2/2019
04:45
I would say hold and watch this space. Olivier was a waste of space. Namal has brought in a strong leadership with particular emphasis on commercial and operations. Exciting times ahead for this great British company and if it does go wrong I would expect take over bid rumours for some on its franchises which will only push up the share price some more. Buy back when share price dips again!
kknight01
07/2/2019
13:41
My view is often too cautious TBF.
essentialinvestor
07/2/2019
11:19
As such, the success of its portfolio will depend on the competitive profile of key, individual products in our view (which we believe looks strong) and how effective the new commercial structure is at promoting those products," he said. M&A seems to be a focus of the new strategic shift, he added, with plenty of balance sheet capacity, having been "fairly inactive in M&A relative to its peers". Looks like new CE is getting to grips - future M&A seems certain.
broadwood
07/2/2019
10:22
Any views folks?, I sold mine at 1487, was not overly impressed tbh. Might be missing something in fairness.
essentialinvestor
07/2/2019
07:38
2019 OutlookOur 2019 guidance for further improvement in underlying performance at the top and bottom line is an important step in realising our medium-term ambition to outgrow our markets.In terms of revenue, we expect our underlying growth to be in the range of 2.5% to 3.5% in 2019. On a reported basis this equates to a range of around 1.8% to 2.8% at exchange rates prevailing on 1 February 2019 and including the effect of the Ceterix acquisition.We expect 2019 trading profit margin to be in the range of 22.8% to 23.2%, a further 40-80bps improvement over 2018, excluding the one-off 50bps legal settlement benefit.The tax rate on trading results for 2019 is expected to be in the range 19% to 21%, subject to any material changes to tax law, or other one-off items.
steeplejack
06/2/2019
15:33
Results tomorrow Revenue: 4.9 nil up from 4.76Profit margin: 22% up from 16%
1fraser
06/2/2019
12:02
Results are tomorrow, in case you are unaware.
essentialinvestor
06/2/2019
07:06
Looks like good support at just about 1400. I'm hoping they continue to rise as we approach results day to about 1500 before pulling back down towards 1450. I think results will be mediocre but won't cause any upset.
kknight01
05/2/2019
17:03
Nice day. Helped by the UKX and FX - weaker GBP.
essentialinvestor
05/2/2019
16:56
onwards and upwards! back over the £15.00 mark?
abbynat
05/2/2019
09:59
Bought a few more SN. Under 1433. Unsure how the market will react so it's a small position, would have liked it closer to £13-13.50, which may be available if the update disappoints.
essentialinvestor
01/2/2019
12:08
The recent Stryker results show what can be achieved with a decent CEO. Think there is a case to me made for selling wound care myself.
essentialinvestor
12/12/2018
11:12
Strange. Nothing spectacular regarding last results. Forecast looks on target and inline with sector. New CEO is 6months in now so is likely going to start making significant change anytime, perhaps Market are expecting good things from Namal.
kknight01
07/12/2018
14:28
Stock up a short 20% in just over 6 weeks in weak market.Bid?
steeplejack
02/11/2018
11:03
Pleased to see the back of Olivier, debatable what he actually achieved. Some very highly priced acquisitions which failed to live up to high expectations?.
essentialinvestor
02/11/2018
08:33
Global medical technology business Smith & Nephew reported a 3% increase in third-quarter underlying revenue and reconfirmed its full-year guidance as it implemented a new global commercial model. The firm said on Thursday that growth in its US and Emerging Markets segments had supported the 3% increase to $1.169bn, "We expect underlying revenue growth to be in the lower half of the 2-3% range and, as a result of a favourable legal settlement and improved cost control, trading profit margin to be above that achieved in 2017," CEO Namal Nawana said. However, revenue declined 1% in its Other Established Markets, where Europe was negatively impacted by challenging conditions in Germany and the UK, while revenue from its Advanced Wound Bioactives franchise fell 7%. Looking forward, the Group did not believe the UK's decision to leave the EU would have a significant impact on its long-term ability to conduct business into and out of the EU or UK. It was making "good progress" with preparations of the various scenarios. In order for the company to leverage its strength as a portfolio medical device company and unlock its growth potential, it was implementing a new global commercial model. Under this, a president would be responsible for each of its three specialised global marketing franchises - Orthopaedics, Sports Medicine/ENT and Wound. Aligned with and supporting the franchises would be presidents and regional commercial organisations for Europe, Middle East, and Africa (EMEA), and Asia Pacific (APAC), while the franchise presidents would also have commercial responsibility for the US.
broadwood
Chat Pages: 36  35  34  33  32  31  30  29  28  27  26  25  Older
ADVFN Advertorial
Your Recent History
LSE
SN.
Smith & Ne..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200529 13:22:40